ArticleNeurosurgical review2014
Invasive adenoma and pituitary carcinoma: a SEER database analysis.
Article in Neurosurgical review, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Metastatic pituitary tumors: an institutional case series.Pituitary · 2023Pooled it
- Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field.Journal of neuro-oncology · 2019Pooled it
- Genetic aspects of pituitary carcinoma: A systematic review.Medicine · 2016Pooled it
- Widespread invasion of a giant prolactinoma via valveless venous channels: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Radiolabeling molecular biomarkers of invasive pituitary adenomas: a narrative review.Pituitary · 2025Review
- Combined Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in the Differential Diagnosis of Sellar Tumors: A Single-Centre Experience.Journal of clinical medicine · 2025Article
- Role of diffusion-weighted imaging in the diagnosis of pituitary region tumors.Neuroradiology · 2025Article
- Spontaneous Cerebrospinal Fluid Rhinorrhea in Pre-operative Pituitary Adenoma: A Report of Two Cases.Cureus · 2024Article
- Prognostic Biomarkers in Pituitary Tumours: A Systematic Review.TouchREVIEWS in endocrinology · 2023Review
- Article
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- Review
- Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case.Journal of neurosurgery. Case lessons · 2023Article
- Identification of biomarkers associated with the invasion of nonfunctional pituitary neuroendocrine tumors based on the immune microenvironment.Frontiers in endocrinology · 2023Article
- PD-L1 and tumor-infiltrating CD8Frontiers in endocrinology · 2023Article
- Pituitary Carcinoma Diagnosis and Survival Improvement, with Affordable Care Act Correlation: A SEER Database Study.Journal of neurological surgery. Part B, Skull base · 2022Article
- High-risk pituitary adenomas and strategies for predicting response to treatment.Hormones (Athens, Greece) · 2022Review
- Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification.Pituitary · 2022Article
- Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004-2016.Scientific reports · 2021Article
- Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.World journal of surgical oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until identification of metastases. Optimal management and survival outcomes for both are not clearly defined. The purpose of this study is to use the Surveillance, Epidemiology, and End Results (SEER) database to report patterns of care and compare survival outcomes in a large series of patients with invasive adenomas or pituitary carcinomas. One hundred seventeen patients diagnosed between 1973 and 2008 with pituitary adenomas/adenocarcinomas were included. Eighty-three invasive adenomas and seven pituitary carcinomas were analyzed for survival outcomes. Analyzed prognostic factors included age, sex, race, histology, tumor extent, and treatment. A significant decrease in survival was observed among carcinomas compared to invasive adenomas at 1, 2, and 5 years (p = 0.047, 0.001, and 0.009). Only non-white race, male gender, and age ≥65 were significant negative prognostic factors for invasive adenomas (p = 0.013, 0.033, and <0.001, respectively). There was no survival advantage to radiation therapy in treating adenomas at 5, 10, 20, or 30 years (p = 0.778, 0.960, 0.236, and 0.971). In conclusion, pituitary carcinoma patients exhibit worse overall survival than invasive adenoma patients. This highlights the need for improved diagnostic methods for the sellar phase to allow for potentially more aggressive treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.